Monoclonal antibodies against stromal derived factor-1 (SDF-1)
US8496931B2 · kind B2 · utility
12Cited by
0References
38Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Aug 10, 2007 |
| Grant date | Jul 30, 2013 |
| Priority date | — |
| Expiry date | Jan 16, 2030 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to SDF-1 with high affinity. Nucleic acid molecules encoding SDF-1 antibodies, expression vectors, host cells and methods for expressing the SDF-1 antibodies are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the SDF-1 antibodies are also provided. Methods for detecting SDF-1, as well as methods for treating various B cell malignancies, including breast cancer, multiple myeloma and non-Hodgkin's lymphoma, and autoimmune disorders are disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.